Pulmatrix, Inc. (PULM): Price and Financial Metrics


Pulmatrix, Inc. (PULM)

Today's Latest Price: $1.07 USD

0.00 (0.00%)

Updated Sep 25 4:00pm

Add PULM to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 373 in Biotech

See all "A" rated Strong Buy stocks

PULM Stock Summary

  • The ratio of debt to operating expenses for Pulmatrix Inc is higher than it is for about merely 10.74% of US stocks.
  • With a year-over-year growth in debt of 202.96%, Pulmatrix Inc's debt growth rate surpasses 92.53% of about US stocks.
  • As for revenue growth, note that PULM's revenue has grown 94.09% over the past 12 months; that beats the revenue growth of 94.47% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Pulmatrix Inc, a group of peers worth examining would be ETTX, AKBA, ARCT, LOGC, and IPHA.
  • Visit PULM's SEC page to see the company's official filings. To visit the company's web site, go to www.pulmatrix.com.
PULM Daily Price Range
PULM 52-Week Price Range

PULM Stock Price Chart Technical Analysis Charts


PULM Price/Volume Stats

Current price $1.07 52-week high $2.06
Prev. close $1.07 52-week low $0.61
Day low $1.05 Volume 350,075
Day high $1.11 Avg. volume 1,080,351
50-day MA $1.21 Dividend yield N/A
200-day MA $1.40 Market Cap 36.82M

Pulmatrix, Inc. (PULM) Company Bio


Pulmatrix, Inc., a clinical stage biopharmaceutical company, engages in developing inhaled therapies to address serious pulmonary diseases using its inhaled Small Particles Easily Respirable and Emitted (iSPERSE) technology. The company was founded in 2003 and is based in Lexington, Massachusetts.


PULM Latest News Stream


Event/Time News Detail
Loading, please wait...

PULM Latest Social Stream


Loading social stream, please wait...

View Full PULM Social Stream

Latest PULM News From Around the Web

Below are the latest news stories about Pulmatrix Inc that investors may wish to consider to help them evaluate PULM as an investment opportunity.

Pulmatrix announces pipeline update

Pulmatrix ([[PULM]] -2.5%) update highlights:The company plans to commence patient dosing for PUR1800 Phase 1b trial in Q1 2021, and expects both the Phase 1b and 6-month toxicology data in Q3 2021. Phase 1b trial data will trigger a $2M milestone payment under the license agreement with J&J announced earlier...

Seeking Alpha | September 22, 2020

Pulmatrix Reports Progress on Product Pipeline

Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, provides an update on product pipeline.

Yahoo | September 22, 2020

Pulmatrix EPS beats by $0.33

Pulmatrix (PULM): Q2 GAAP EPS of -$0.05 beats by $0.33.Revenue of $3.5M (-27.4% Y/Y)Press Release...

Seeking Alpha | August 7, 2020

Pulmatrix Reports Q2 2020 Results and Business Updates

LEXINGTON, Mass., Aug. 7, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, today reports its Q2 2020…

PR Newswire | August 7, 2020

Pulmatrix Announces Progress by Sensory Cloud Toward Commercial Launch of FEND in Fall 2020, an OTC Nasal Hygiene Product Designed to Suppress Exhaled Airborne Particles

LEXINGTON, Mass., July 8, 2020 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to serious pulmonary and non-pulmonary disease using its patented iSPERSE™ technology, announced that Sensory Cloud, which…

PR Newswire | July 8, 2020

Read More 'PULM' Stories Here

PULM Price Returns

1-mo -3.60%
3-mo -43.09%
6-mo -2.73%
1-year 30.49%
3-year -94.95%
5-year -97.82%
YTD 24.42%
2019 -64.17%
2018 -82.98%
2017 138.98%
2016 -85.95%
2015 -52.00%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6678 seconds.